Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma

被引：9

作者：

Kohl, LP ^{[1
]}

Lim, LC ^{[1
]}

Thng, CH ^{[1
]}

机构：

[1] Singapore Gen Hosp, Dept Haematol, Singapore 169608, Singapore

来源：

MEDICAL ONCOLOGY | 2000年 / 17卷 / 03期

关键词：

nodal marginal zone B-cell lymphoma; Rituximab; retreatment;

D O I：

10.1007/BF02780533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A patient with advanced and chemotherapy-refractory nodal marginal zone B-cell lymphoma was given a course of chimeric CD20 monoclonal antibody Rituximab. Partial response was observed without any major toxicities. Retreatment with Rituximab for disease progression six months after the first course led to partial remission. Adjuvant radiotherapy was given for the residual disease and, currently, patient's disease remains stable eight months after the second course of Rituximab, This case demonstrates the therapeutic efficacy and feasibility of retreatment with Rituximab for relapsed or refractory low grade lymphoma.

引用

页码：225 / 228

页数：4

共 13 条

[1] LIVER BIOPSY IN HODGKINS-DISEASE - CLINICOPATHOLOGIC CORRELATIONS IN 127 PATIENTS [J].

BAGLEY, CM ;

ROTH, JA ;

THOMAS, LB ;

DEVITA, VT .

ANNALS OF INTERNAL MEDICINE, 1972, 76 (02) :219-+

[2]

CABANILLAS F, 1982, BLOOD, V60, P693

[3]

Chan WC, 1997, BLOOD, V89, P3909

[4]

CRUCZMAN MS, 1999, J CLIN ONCOL, V17, P268

[5]

DAVIS T, 1997, 39 ANN M AM SOC HEM

[6] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab [J].

Davis, TA ;

White, CA ;

Grillo-López, AJ ;

Velásquez, WS ;

Link, B ;

Maloney, DG ;

Dillman, RO ;

Williams, ME ;

Mohrbacher, A ;

Weaver, R ;

Dowden, S ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1851-1857

[7] Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) [J].

Jensen, M ;

Winkler, U ;

Manzke, O ;

Diehl, V ;

Engert, A .

ANNALS OF HEMATOLOGY, 1998, 77 (1-2) :89-91

[8]

Lim LC, 1999, J CLIN ONCOL, V17, P1962

[9] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[10]

Nathwani BN, 1999, SEMIN HEMATOL, V36, P128

← 1 2 →